55939
document
[ Localised prostate cancer : the PREFERE trial ] . Prostate cancer is the most common carcinoma of the elderly man and holds the third place in the ranking of cancer-specific mortality . However , mortality rates of 3 % are low , and half of the patients will die from intercurrent disease . Due to the significantly improved diagnostic methods and the increasing use of PSA screening , there has been a stage migration towards early tumour stages that are prognostically heterogeneous and require differentiated treatment . Based on the discussions of the Joint Federal Committee ( G-BA ) and the conceptual work of the MDS , the Competence Centre Oncology of the MDK , the IQWIG and the National Association of Statutory Health Insurance Funds ( GKV-Spitzenverband ) , a prospective randomised multicentre trial was developed comparing the four treatments actually recommended by the German and European guidelines for localised prostate cancer ( radical prostatectomy , percutaneous radiotherapy and permanent seed implantation and active surveillance ) allowing a rejection of one or two treatment options . The trial is expected to start at the beginning of next year .
55940
Intervention_Surgical
radical prostatectomy
55941
Intervention_Physical
percutaneous radiotherapy
55942
Intervention_Physical
permanent seed implantation
55943
Intervention_Physical
active surveillance
55944
Outcome_Mortality
cancer-specific mortality
55945
Outcome_Mortality
mortality rates
55946
Outcome_Other
radical prostatectomy
55947
Outcome_Other
percutaneous radiotherapy
55948
Outcome_Other
permanent seed implantation
55949
Outcome_Other
active surveillance
55950
Participant_Condition
[ Localised prostate cancer :
55951
Participant_Condition
carcinoma